Persistent Systems has unveiled a new AI-powered generative molecules and virtual screening solution, developed in collaboration with NVIDIA. The innovation leverages NVIDIA’s BioNeMo framework to accelerate drug discovery, enabling healthcare and life sciences organizations to identify potential therapies faster, reduce costs, and improve research outcomes.
The launch marks a significant milestone in computational drug discovery. Persistent Systems, a leader in digital engineering, is partnering with NVIDIA to bring advanced generative AI and analytics to the healthcare and life sciences sector, addressing challenges in early-stage drug development.
Technology And Innovation
The solution integrates generative AI models with virtual screening techniques, dramatically reducing the need for traditional lab-based testing. By simulating thousands of chemical compounds digitally, researchers can identify promising drug candidates more efficiently. NVIDIA’s BioNeMo framework provides the computational power and scalability required for these complex tasks.
Industry Impact
Persistent Systems’ collaboration with NVIDIA is expected to transform drug discovery workflows. With regulatory agencies prioritizing safer and more selective drugs, this AI-powered solution will help pharmaceutical companies and research institutions accelerate innovation while maintaining compliance in highly regulated environments.
Key Highlights
-
Persistent Systems launches AI-powered drug discovery solution
-
Developed in collaboration with NVIDIA BioNeMo framework
-
Focuses on generative molecules and virtual screening
-
Reduces costs and accelerates early-stage drug discovery
-
Targets healthcare and life sciences industry innovation
Sources: Persistent Systems, Economic Times, Reuters